BioTechnology
Ganymede Bio Launches Industry-First Gxp-Native Developer Platform And Data Infrastructure For Wet Lab Data
By Business Wire
Share
PALO ALTO, Calif.--(BUSINESS WIRE)--Ganymede Bio, the wet lab data platform and integration builder for the life sciences and manufacturing, today announced the public launch of its GxP Data Automation Platform, or “GDP”. GDP extends Ganymede’s core Lab-as-Code platform by leveraging its traceability framework, itself designed with GxP at its core, to support an entire GxP software development lifecycle within the platform for lab data capture and automation. This includes:
- Enhanced code versioning and locking controls on Lab-as-Code’s backing git repos
- Deep audit log functionality to monitor data and configuration changes
- Specialized tenants for GxP use cases including GMP, with the ability to cherry-pick releases
- A GxP documentation package to assist with validation & verification
"Ganymede's platform is the first and only GxP-native developer infra for the wet lab and biomanufacturing. The traceability model inherent in our Lab-as-Code flows makes it easy to know what instrument and what data ran through what code to get to a result, for every single assay,” said Andy Caruso, Head of Engineering at Ganymede Bio.
Using GDP, Ganymede and its clients can implement full data capture and automation workflows in code via Lab-as-Code, in a way that is controlled, documented, and ready for validation. No developer platform currently exists to develop code and workflows that is designed for GxP use cases from the ground up and offers an entire onboard software development lifecycle and infrastructure environment for lab data, down to the level of having an integrated development environment, or “IDE”, onboard the application for code editing that is forced into the traceability model.
“Ganymede is revolutionizing the life sciences one dataset at a time, and it’s incredible to see the breadth of clients ranging from R&D to highly regulated manufacturing. Opening GDP and our GxP capabilities to the broader market is the natural next step,” said Varun Gupta, General Partner at Caffeinated Capital and director on Ganymede’s board.
Ganymede has been developing GDP over the course of much of 2023 and 2024, and in response to strong market demand, the company aims to launch GDP now to begin locking in 2025 implementations with clients in the broader market to capture data, automate analysis, and automate LIMS data entry primarily in the GMP space.
Nathan Clark, Cofounder and CEO of Ganymede said that “the transition from paper to digital paid powerful dividends, but it didn’t absolve us of the risks of human data entry. Now, through data automation, we can maximize data integrity and traceability for compliance, while simultaneously savings scientists and operators time. The key is removing the human element in your data flows. We’ve done this to great effect in preclinical spaces to date, and are excited to begin rolling out Ganymede to GxP use cases via GDP.”
About Ganymede
Ganymede Bio is the wet lab data platform and integration builder for the life sciences and manufacturing industries. The company’s Lab-as-Code™ technology captures data and metadata from physical lab instruments, automates analysis and data product creation, and pushes it to applications such as electronic lab notebooks (ELNs) and laboratory information management systems (LIMS) in a single cloud data layer. Ganymede accelerates time to innovation by giving scientists the ability to automate the world around them using cloud-controlled data flows. Launch your lab of the future today by visiting us at www.ganymede.bio.
Contacts
Ganymede
Mays Alwash
Business Development
press@ganymede.bio
First published on Wed, Sep 4, 2024
Enjoyed what you read? Great news – there’s a lot more to explore!
Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!
Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.
Head to the TechDogs homepage to Know Your World of technology today!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. All information / content found on TechDogs' site may not necessarily be reviewed by individuals with the expertise to validate its completeness, accuracy and reliability.
Tags:
Related News on BioTechnology
Evonetix Closes $24 Million USD (20 Million) Financing
Tue, Feb 7, 2023
By Business Wire
Kane Biotech Strengthens Board With Biotech Executive
Fri, Nov 17, 2023
By GlobeNewswire
Trinity Life Sciences And WhizAI Announce Partnership
Wed, Apr 26, 2023
By Business Wire
Kiromic BioPharma Announces Uplisting To OTCQB Market
Fri, Nov 17, 2023
By Business Wire
Trending Business Wire
Halan And Truecaller Collaborate To Redefine Communication Safety In Egypts Fintech Landscape
By Business Wire
Houston Area School District Is First In Texas To Add Powerschool AI Assistant Powerbuddy To Classrooms
By Business Wire
KAYTUS Unveils Next-Generation Air-Cooled Containerized AI Computing
By Business Wire
Mahindra & Mahindra Selects Kinaxis To Drive Supply Chain Efficiencies For Growing Automotive Portfolio
By Business Wire
Neo Financial Ranks No. 1 On The Globe And Mails 2024 List Of Canadas Top Growing Companies
By Business Wire
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion